Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Wells, George A ^a   Cranney, A ^b   Peterson, J ^b   Boucher, M ^b   Shea, B ^b   Robinson, V ^b   Coyle, D ^b   Tugwell, P ^b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; ETIDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; SILVER; BONE DENSITY CONSERVATION AGENT;

ABDOMINAL PAIN; BONE NECROSIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIGESTIVE SYSTEM INJURY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; ENDOCRINE DISEASE; ESOPHAGITIS; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FOLLOW UP; FRAGILITY FRACTURE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HIP FRACTURE; HOT FLUSH; HUMAN; INFECTION; KIDNEY DISEASE; META ANALYSIS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; ODYNOPHAGIA; PEPTIC ULCER; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SKIN DISEASE; STOMACH ULCER; SYSTEMATIC REVIEW; TREATMENT DURATION; URINARY TRACT DISEASE; VERTEBRA FRACTURE; VISUAL DISORDER; VOMITING; WRIST FRACTURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG FORMULATION; INCIDENCE; INFORMATION PROCESSING; MEDICAL RESEARCH; PROPHYLAXIS; PUBLICATION; RISK FACTOR; STATISTICAL SIGNIFICANCE; TEMPOROMANDIBULAR JOINT; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; FEMALE; FRACTURE; PATHOLOGIC FRACTURE; SPINE FRACTURE;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; FRACTURES, SPONTANEOUS; HIP FRACTURES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL FRACTURES;

EID: 44949191491     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001155.pub2     Document Type: Review

References (122)

1. Ascott Evans 2003 {published data only} Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, et al.Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Archives of Internal Medicine 2003;163(7):789-94.
2. Black 1996 {published data only} *Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al.Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.[see comment]. Lancet 1996;348(9041):1535-41.
3. Bone 1997 {published data only} *Bone HG, Downs RW Jr, Tucci JR, Harris ST, Weinstein RS, Licata AA, et al.Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. Journal of Clinical Endocrinology & Metabolism 1997;82(1):265-74.
4. Chestnut 1995 {published data only} *Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, et al.Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. American Journal of Medicine 1995;99(2):144-52.
5. Cummings 1998 {published data only} *Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al.Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. [see comment]. JAMA 1998;280(24):2077-82.
6. Durson 2001 {published data only} Dursun N, Dursun E, Yalcin S. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. International Journal of Clinical Practice 2001;55(8):505-9.
7. Greenspan 1998 {published data only} *Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. 1998;13(9):1431-8.
8. Greenspan 2002 {published data only} Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, et al.Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. [see comment]. Mayo Clinic Proceedings 2002;77(10):1044-52.
9. Hosking 1998 {published data only} *Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, et al.Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. New England Journal of Medicine 1998;338(8):485-92.
10. Liberman 1995 {published data only} Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al.Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. [see comment]. New England Journal of Medicine 1995;333(22):1437-43.
11. Pols 1999 {published data only} *Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, et al.Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporosis International 1999;9(5):461-8.
12. Adami 1993 Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, et al.Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporosis International 1993;3 Suppl 3:S21-S27.
13. Adami 1995 Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, et al.Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17(4):383-90.
14. Aki 2003 Aki S, Gulbaba RG, Eskiyurt N. Effect of alendronate on bone density and bone markers in postmenopausal osteoporosis. Journal of Back & Musculoskeletal Rehabilitation 2003;17(1). [MEDLINE: 669].
15. Bell 2002 Bell NH, Bilezikian JP, Bone HG III, Kaur A, Maragoto A, Santora AC, Study Group. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. Journal of Clinical Endocrinology & Metabolism 2002;87(6):2792-7.
16. Bettembuk 1999 Bettembuk P, Balogh A. [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungarian of an international multicenter clinical study)]. Orvosi Hetilap 1999;140(50):2799-803.
17. Black 2000 Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al.Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. [erratum appears in J Clin Endocrinol Metab 2001 Feb;86(2):938]. Journal of Clinical Endocrinology & Metabolism 2000;85(11):4118-24.
18. Black 2003 Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al.The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. [see comment]. New England Journal of Medicine 2003;349(13):1207-15.
19. Body 2002 Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al.A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone (1-34)) with alendronate in postmenopausal women with osteoporosis. [see comment]. Journal of Clinical Endocrinology & Metabolism 2002;87(10):4528-35.
20. Boivin 2000 Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27(5):687-94.
21. Bone 2000 Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, et al.Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. Journal of Clinical Endocrinology & Metabolism 2000;85(2):720-6.
22. Bone 2004 Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al.Ten years' experience with alendronate for osteoporosis in postmenopausal women. [see comment]. New England Journal of Medicine 2004;350(12):1189-99.
23. Bonnick 1998 Bonnick S, Rosen C, Mako B, DeLucca P, Byrned C, Melton M. Alendronate vs calcium for treatment of osteoporosis in postmenopausal women. Bone 1998;350(5S):S476.
24. Bouxsein 1999 Bouxsein ML, Parker RA, Greenspan SL. Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women. Osteoporosis International 1999;10(6): 505-9.
25. Chailurkit 2003 Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-tung S, Rajatanavin R. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. Journal of Bone & Mineral Metabolism 2003;21(6):421-7.
26. Chailurkit 2004 Chailurkit LO, Aunphongpuwanart S, Ongphiphadhanakul B, Jongjaroenprasert W, Sae-tung S, Rajatanavin R. Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis. Endocrine Research 2004;30(1):29-36.
27. Chavassieux 1997 Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. Journal of Clinical Investigation 1997;100(6):1475-80.
28. Cheng 2002 Cheng ZQ, Yin W, Fan JY, Ma TJ. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis]. [Chinese]. Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae 2002;24(3):306-9.
29. Chesnut 1993 Chesnut CH, Harris ST. Short term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporosis International 1993;3(Suppl 3):S17-S19.
30. Cummings 2000 Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al.Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 2000;283(10):1318-21.
31. Davas 2003 Davas I, Altintas A, Yoldemir T, Varolan A, Yazgan A, Baksu B. Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women. Fertility & Sterility 2003;80(3):536-40.
32. Devogelaer 1996 Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, et al.Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. [erratum appears in Bone 1996 Jul;19(1):78]. Bone 1996;18(2):141-50.
33. Dobnig 2006 Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A, Dobnig H, et al.Changes in the RANK ligand/ osteoprotegerin systemare correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporosis International 2006;17(5):693-703. [MEDLINE: 13].
34. Downs 2000 Downs RW Jr, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, et al.Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. Journal of Clinical Endocrinology & Metabolism 2000;85(5):1783-8.
35. Evio 2004 Evio S, Tiitinen A, Laitinen K, Ylikorkala O, Valimaki MJ. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. Journal of Clinical Endocrinology & Metabolism 2004;89(2):626-31.
36. Gonnelli 2002 Gonnelli S, Cepollaro C, Montagnani A, Martini S, Gennari L, Mangeri M, et al.Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study. Osteoporosis International 2002;13(5):415-21.
37. Greenspan 2002a Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, et al.Significant differential effects of alendronate, estrogen or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. [summary for patients in Ann Intern Med. 2002 Dec 3;137(11):I31; PMID: 12459003]. Annals of Internal Medicine 2002;137(11):875-83.
38. Greenspan 2002b Greenspan SL, Schneider DL, McClung MR, Miller PD, Schnitzer TJ, Bonin R, et al.Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. [summary for patients in Ann Intern Med. 2002 May 21;136(10):I54; PMID: 12020160]. Annals of Internal Medicine 2002;136(10):742-6.
39. Greenspan 2003 Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003;289(19): 2525-33.
40. Harris 1993 Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, et al.The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. Journal of Clinical Endocrinology & Metabolism 1993;76(6):1399-1406.
41. Heijckmann 2002 Heijckmann AC, Juttmann JR, Wolffenbuttel BH. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. [see comment]. Netherlands Journal of Medicine 2002;60(8):315-9.
42. Ho 2005 Ho AY, Kung AW, Ho AYY, Kung AWC. Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. Annals of Pharmacotherapy 2005;39(9):1428-33. [MEDLINE: 109].
43. Hochberg 1999 Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, et al.Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis & Rheumatism 1999;42(6):1246-54.
44. Hosking 2003 Hosking D, Adami S, Felsenberg D, Andia JC, Valimaki M, Benhamou L, et al.Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Current Medical Research & Opinion 2003;19(5):383-94.
45. Iwamoto 2004 Iwamoto J, Takeda T, Sato Y, Uzawa M. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis. Yonsei Medical Journal 2004;45(4):676-82.
46. Johnell 2002 Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. [see comment]. Journal of Clinical Endocrinology & Metabolism 2002;87(3):985-92.
47. Kung 2000 Kung AW, Yeung SS, Chu LW. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study. Calcified Tissue International 2000;67(4):286-90.
48. Kushida 2004 Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, et al.Alendronate reduced vertebral fracture risk in post-menopausal Japanese women with osteoporosis: a 3-year follow-up study. Journal of Bone & Mineral Metabolism 2004;22(5):462-8.
49. Lau 2000 Lau EM, Woo J, Chan YH, Griffith J. Alendronate prevents bone loss in Chinese women with osteoporosis. Bone 2000;27(5):677- 80.
50. Luckey 2004 Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, et al.Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004;11(4): 405-15.
51. Malavolta 1999 Malavolta N, Zanardi M, Veronesi M, Ripamonti C, Gnudi S. Calcitriol and alendronate combination treatment in menopausal women with low bone mass. International Journal of Tissue Reactions 1999;21(2):51-9.
52. McClung 1998 McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, et al.Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. [see comment]. Annals of Internal Medicine 1998;128(4):253-61.
53. McClung 2004 McClung MR, Wasnich RD, Hosking DJ, Christiansen C, Ravn P, Wu M, et al.Prevention of postmenopausal bone loss: six-year results fromthe Early Postmenopausal Intervention Cohort Study. Journal of Clinical Endocrinology & Metabolism 2004;89(10):4879-85. [MEDLINE: 190].
54. Murphy 2001 Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, et al.Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Journal of Clinical Endocrinology & Metabolism 2001;86(3):1116-25.
55. Nenonen 2005 Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gayk H, et al.Serum TRACP 5b is a useful marker for monitoring alendronate treatment: Comparison with other markers of bone turnover. Journal of Bone & Mineral Research 2005;20(8):1804-12. [MEDLINE: 576].
56. Palomba 2002 Palomba S, Orio F Jr, Colao A, di Carlo C, Sena T, Lombardi G, et al.Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. Journal of Clinical Endocrinology & Metabolism 2002;87(4): 1502-8.
57. Payer 2000 Payer J Jr, Killinger Z, Masaryk P, Tomkova S, Kmecova Z, Ondrejkova J, et al.[Effect of alendronate therapy on bone turnover - results of a multicenter study]. [Slovak]. Vnitrni Lekarstvi 2000;46(10):689-92.
58. Ravn 1999a Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999;24(3):237-44.
59. Ravn 1999b Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, et al.Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. Journal of Clinical Endocrinology & Metabolism 1999;84(7):2363-8.
60. Ravn 1999c Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al.Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. [see comment]. Annals of Internal Medicine 1999;131(12):935-42.
61. Ravn 2000 Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, et al.Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. Journal of Clinical Endocrinology & Metabolism 2000;85(4):1492-7.
62. Rhee 2006 Rhee Y, Kang M, Min Y, Byun D, Chung Y, Ahn C, et al.Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Osteoporosis International 2006;17(12):1801-7. [MEDLINE: 7].
63. Rittmaster 2000 Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, et al.Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. [see comment]. Journal of Clinical Endocrinology & Metabolism 2000;85(6):2129-34.
64. Rizzoli 2002 Rizzoli R, Greenspan SL, Bone G III, Schnitzer TJ, Watts NB, Adami S, et al.Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. Journal of Bone & Mineral Research 2002;17(11):1988-96.
65. Rossini 1994 Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. Journal of Bone & Mineral Research 1994;9(11):1833-7.
66. Rossini 2000 Rossini M, Gatti D, Girardello S, Braga V, James G, Adami S. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone 2000;27(1):119-22.
67. Rozkydal 2003 Rozkydal Z, Janicek P. The effect of alendronate in the treatment of postmenopausal osteoporosis. Bratislavske Lekarske Listy 2003;104(10):309-13.
68. Sahota 2000 Sahota O, Fowler I, Blackwell PJ, Lawson N, Cawte SA, San P, et al.A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial. Osteoporosis International 2000;11(11):959-66.
69. Sambrook 2004a Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, et al.Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. Journal of Internal Medicine 2004;255(4): 503-11.
70. Sambrook 2004b Sambrook PN, Rodriguez JP, Wasnich RD, Luckey MM, Kaur A, Meng L, et al.Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporosis International 2004;15(6):483-8.
71. Sawka 2003 Sawka AM, Adachi JD, Ioannidis G, Olszynski WP, Brown JP, Hanley DA, et al.What predicts early fracture or bone loss on bisphosphonate therapy?. Journal of Clinical Densitometry 2003;6(4):315-22.
72. Schneider 1999 Schneider PF, Fischer M, Allolio B, Felsenberg D, Schroder U, Semler J, et al.Alendronate increases bone density and bone strength at the distal radius in postmenopausal women. Journal of Bone & Mineral Research 1999;14(8):1387-93.
73. Schnitzer 2000 Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al.Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging-Clinical & Experimental Research 2000;12(1):1-12.
74. Seeman 1999 Seeman E. The antifracture efficacy of alendronate. International Journal of Clinical Practice 1999;Supplement. 101:40-5.
75. Simon 2002 Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clinical Therapeutics 2002;24(11):1871-86.
76. Sosa 2002 Sosa M, Hernandez D, Segarra MC, Gomez A, de la PE, Betancor P. Effect of two forms of alendronate administration upon bone mass after two years of treatment. Journal of Clinical Densitometry 2002;5(1):27-34.
77. Stepan 1999 Stepan JJ, Vokrouhlicka J. Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. Clinica Chimica Acta 1999;288(1-2):121-35.
78. Tiras 2000 Tiras MB, Noyan V, Yildiz A, Yildirim M, Daya S. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Human Reproduction 2000;15(10):2087-92.
79. Tucci 1996 Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. American Journal of Medicine 1996;101(5):488-501.
80. Tutuncu 2005 Tutuncu L, Arslanhan N, Mungen E, Yilmaz S, Yergok YZ. Combined usage of raloxifene and alendronate: Effects on biochemical markers. [Turkish]. Nobel Medicus 2005;1(2). [MEDLINE: 519].
81. Uusi-Rasi 2003 Uusi-Rasi K, Kannus P, Cheng S, Sievanen H, Pasanen M, Heinonen A, et al.Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. Bone 2003;33(1):132-43.
82. van der Poest 2000 van der Poest CE, Patka P, Vandormael K, Haarman H, Lips P. The effect of alendronate on bone mass after distal forearm fracture. Journal of Bone & Mineral Research 2000;15(3):586- 93.
83. Vasikaran 1995 Vasikaran SD, Khan S, McCloskey EV, Kanis JA. Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone 1995;17(6):517-20.
84. Yen 2000 Yen ML, Yen BL, Jang MH, Hsu SH, Cheng WC, Tsai KS. Effects of alendronate on osteopenic postmenopausal Chinese women. Bone 2000;27(5):681-5.
85. Yildirim 2005 Yildirim K, Gureser G, Karatay S, Melikoglu MA, Ugur M, Erdal A, et al.Comparison of the effects of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis. Journal of Back & Musculoskeletal Rehabilitation 2005;18(3-4). [MEDLINE: 540].
86. Black 2000b Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85(11):4118-24.
87. Black 2001 Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, et al.An assessment tool for predicting fracture risk in postmenopausal women. Osteoporosis International 2001;12(7):519- 28.
88. Black 2006 Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al.Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38.
89. Brown 2002 Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 Suppl):S1-34.
90. Browner 1996 Browner WS, Pressman AR, Nevitt MC, Cummings SR. Mortality following fractures in older women. The study of osteoporotic fractures. Archives of Internal Medicine 1996;156(14):1521-5.
91. CADTH 2006 Coyle D, Hadj Tahar A, Murphy G, Perras C, Skidmore B, Boucher M, et al.Teriparatide and bisphosphonates of treatment of osteoporosis in women: a clinical and economic analysis. Canadian Agency for Drugs and Technologies in Health 2006.
92. Cates 2004 Cates C. Visual Rx NNT Calculator 2.0. Dr. Chris Cates EBM website. Available from: URL: http://www.nntonline.net/, 2004.
93. Cauley 2000 Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporosis International 2000;11(7):556-61.
94. Cooper 1993 Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ III. Population-based study of survival after osteoporotic fractures. American Journal of Epidemiology 1993;137(9):1001-5.
95. Cranney 2002 Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, et al.Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Reviews 2002;23(4):508-16.
96. Cummings 1989 Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Archives of Internal Medicine 1989;149(11): 2445-8.
97. Dickersin 1994 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286- 91.
98. Doherty 2001 Doherty DA, Sanders KM, Kotowicz MA, Prince RL. Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporosis International 2001;12(1):16-23.
99. Egger 2003 Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technology Assessment 2003;7(1):1-76.
100. Fleiss 1993 Fleiss JL. The statistical basis of meta-analysis. Statistical Methods in Medical Research 1993;2(2):121-45.
101. GRADE 2004 Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al.Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
102. Hanley 2003 Hanley DA. Osteoporosis. In: GrayJ editor(s). Therapeutic Choices. 4th Edition. Ottawa: Canadian Pharmaceutical Association, 2003:637-46.
103. Harris 1999 Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al.[Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group]. JAMA 1999;282(14):1344-52.
104. Health Canada 2005 Canadian Adverse Drug Reaction Monitoring Program. Alendronate. In: Health Canada, editor(s). Adverse Reaction Database. Ottawa: 2005.
105. Health Canada 2005c Health Canada. Medeffect [website]. Health Canada 2005.
106. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
107. Hodsman 2002 Hodsman AB, Hanley DA, Josse R. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ 2002;166(11):1426-30.
108. Kanis 1994 Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. Journal of Bone and Mineral Research 1994;9(8):1137-41.
109. Kherani 2002 Kherani RB, Papaioannou A, Adachi JD. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review. Drug Safety 2002;25(11):781-90.
110. Khosla 2007 Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al.Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 2007;22(Khosla 2007):1479-91.
111. Mavrokokki 2007 Mavrokokki T, Cheng A, Stein B, Gross A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. Journal of Oral and Maxillofacial Surgery 2007;65:415- 23.
112. Mayo Clin Proc 2005 Alendronate and vertebral fracture risk [multiple letters]. Mayo Clin Proc YR:2005 Vol. 80:1233-41.
113. McClung 2001 McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al.Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. [see comment]. New England Journal of Medicine 2001;344(5):333-40.
114. Melton 1989 Melton LJ III, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. American Journal of Epidemiology 1989;129(5):1000-11.
115. NIH Consensus 2001 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95.
116. Rodan 1993 Rodan GA, Seedor JG, Balena R. Preclinical phamacology of alendronate. Osteoporosis International 1993;3(Suppl 3):S7-12.
117. Sampson 2003 Sampson M, Barrowman NJ, Moher D, Klassen TP, Pham B, Platt R, et al.Should meta-analysts search Embase in addition to Medline?. Journal of Clinical Epidemiology 2003;56(10):943-55.
118. Shukla 2003 Shukla V. Treating osteoporosis with teriparatide: many unknowns? [Issues in emerging health technologies issue 51]. 2003.
119. Tugwell 2004 In: TugwellP, SheaB, BoersM, BrooksP, SimonS, StrandV, WellsG editor(s). Evidence-Based Rheumatology. London: BMJ Books, 2004.
120. WHO 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group. World Health Organ Tech Rep Ser 1994;843:1-129.
121. Woo 2006 Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine 2006;144(10):753-61.
122. CADTH 2006b Wells GA, Cranney A, Bouchere M, Peterson J, Shea B, Robinson V, et al.Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no 69]. Ottawa: Canadian Agency for Drugs and Technologies in Health 2006.